Zanosar (streptozocin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Streptozocin is an antineoplastic antibiotic produced by Streptomyces achromogenes.
Generic name: streptozocin
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zanosar
Indications
The following indications are listed for Zanosar:
- Pancreatic Neuroendocrine Tumor
Also known as: Malignant Tumor Of Islets Of Langerhans.
Dosing
Because streptozocin is classified as an antineoplastic agent of high emetic risk, antiemetic therapy for the prevention of acute and delayed emesis is recommended. (See Cautions: GI Effects.)
Dosage of streptozocin must be based on the clinical, renal, hematologic, and hepatic response and tolerance of the patient in order to obtain optimum therapeutic results with minimum adverse effects. Clinicians should consult published protocols for the dosage of streptozocin and other chemotherapeutic agents and the method and sequence of administration. A repeat course of streptozocin should not be administered until the patient's renal, hematologic, and hepatic functions are within acceptable limits. (See Cautions: Precautions and Contraindications.)
Although the effects of renal impairment on the elimination of streptozocin have not been evaluated, some clinicians have suggested that patients with creatinine clearances of 10-50 mL/minute receive 75% of the usual dose and those with creatinine clearances less than 10 mL/minute receive 50% of the usual dose.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Although there are no adequate and controlled studies to date in humans, streptozocin has been shown to be teratogenic in rats and has an abortifacient effect in rabbits. Streptozocin should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
It is not known if streptozocin is distributed into milk. Because of the potential for serious adverse reactions to streptozocin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.